Table 5.
The risks of side effects between different genetic marker groups by logistic regression analysis (n = 189)
| Side effect | Variable | Beta‐standardized coefficients | P value | OR | 95% CI | |
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Leukocytopenia | PM vs. IM | −0.214 | 0.788 | 0.808 | 0.171 | 3.826 |
| EM vs. IM | 2.020 | <0.0001 | 7.538 | 2.951 | 19.256 | |
| Infection | PM vs. IM | −19.929 | 0.999 | 0 | 0 | 0 |
| EM vs. IM | 0.646 | 0.179 | 1.907 | 0.744 | 4.886 | |
| GI toxicity | PM vs. IM | −19.265 | 0.999 | 0 | 0 | 0 |
| EM vs. IM | 2.025 | <0.0001 | 7.579 | 2.934 | 19.578 | |
EM, extensive metabolizer, patients with CYP2C19*1*1 and CYP2B6 ‐750TT;
IM, intermediate metabolizer, patients with any other combination of these genotypes other than EM and PM;
PM, poor metabolizer, patients with CYP2C19*2*2 and CYP2B6 ‐750CC.